Monroy Guízar Elisa Alejandra, García Benavides Leonel, Ambriz Plascencia Ana Rosa, Pascoe González Sara, Totsuka Sutto Sylvia Elena, Cardona Muñoz Ernesto German, Méndez-Del Villar Miriam
1 Institute of Experimental and Clinical Therapeutics, Health Science University Center, University of Guadalajara , Guadalajara, Jalisco, México .
2 Civil Hospital of Guadalajara 'Fray Antonia Alcalde', Guadalajara, Jalisco, México .
J Med Food. 2018 May;21(5):521-526. doi: 10.1089/jmf.2017.0056. Epub 2018 Jan 22.
The objective of our study was to examine the effect of alpha-lipoic acid (ALA) on clinical and neurophysiologic outcomes after surgery for idiopathic carpal tunnel syndrome (CTS). We conducted a randomized, double-blind, placebo-controlled clinical trial in 20 adults diagnosed with idiopathic CTS after clinical and neurophysiologic assessment. Eligible participants took 600 mg ALA or placebo per day for 1 month before surgery, and for 2 months afterward. Further clinical and neurophysiologic assessments were undertaken immediately before surgical decompression, and at 12 weeks postoperatively with additional clinical assessments at the 4th and 8th week after surgery. Clinical outcome measures were taken by Boston Questionnaire score, the presence or absence of Tinel's sign, and Phalen's test findings. Median nerve conduction studies were also undertaken and interpreted according to Dumitru's reference values. Nineteen patients completed the study; one member of the placebo group was lost during follow-up. There were significant improvements in clinical and neurophysiologic variables in the ALA treatment group, present even before surgery. Boston Questionnaire scores had improved significantly in both groups. In the ALA group, none of the participants had positive Phalen's or Tinel's signs at 12 weeks, and motor and sensory fiber latency and amplitude had significantly improved; in the placebo group, only the sensory distal latency had improved significantly. In conclusion, ALA administered 1 month before open decompression and for 2 months afterward improves the clinical and neurophysiologic outcomes after surgery.
我们研究的目的是检验α-硫辛酸（ALA）对特发性腕管综合征（CTS）手术后临床和神经生理学结果的影响。我们对20名经临床和神经生理学评估确诊为特发性CTS的成年人进行了一项随机、双盲、安慰剂对照临床试验。符合条件的参与者在手术前1个月每天服用600毫克ALA或安慰剂，并在术后持续2个月。在手术减压前以及术后12周立即进行进一步的临床和神经生理学评估，并在术后第4周和第8周进行额外的临床评估。临床结果通过波士顿问卷评分、Tinel征的有无以及Phalen试验结果来衡量。还进行了正中神经传导研究，并根据Dumitru的参考值进行解读。19名患者完成了研究；安慰剂组的一名成员在随访期间失访。ALA治疗组的临床和神经生理学变量有显著改善，甚至在手术前就已出现。两组的波士顿问卷评分均有显著改善。在ALA组中，12周时没有参与者的Phalen征或Tinel征呈阳性，运动和感觉纤维潜伏期及波幅有显著改善；在安慰剂组中，只有感觉远端潜伏期有显著改善。总之，在开放减压前1个月及术后2个月给予ALA可改善手术后的临床和神经生理学结果。
